Aktuellt
SENASTE
Redeye shares its initial take on Genovis’ Q4´21 report. We regard it as a solid report and find it reassuring to see that the company is returning with high sales growth of enzymes in the core Analytics segment (+35% y/y), even though we viewed the third quarter as just a bump in the road. With societies opening up again and things gradually getting back to normal, we foresee a strong outlook for Genovis going forward and the share is one of Redeye’s Life Science Top Picks for 2022.
LÄS MER
